Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure Inc. (MCUJF) generates regular news flow through financial results, pharmacy acquisitions and updates on its U.S. pharmaceutical and healthcare product operations. The company describes itself as focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, with a present focus on AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets.
News items commonly include quarterly and year-end financial results, where Medicure reports revenue from AGGRASTAT, ZYPITAMAG, and its pharmacy businesses. These releases often discuss performance of Marley Drug, Gateway Medical Pharmacy and West Olympia Pharmacy, as well as research and development spending, including work on the investigational product MC-1 for PNPO deficiency.
Investors following MCUJF can also find announcements about corporate transactions, such as the acquisitions of Gateway Medical Pharmacy and West Olympia Pharmacy through Medicure’s U.S. subsidiary. The company’s news regularly provides details on how these acquisitions relate to its direct-to-consumer pharmacy expansion and support for marketed products like ZYPITAMAG and BRENZAVVY.
Medicure also issues notices about upcoming investor conference calls and webcasts for its quarterly and annual results, including dial-in details and access codes. This news page aggregates those releases so readers can review historical announcements and monitor ongoing developments in Medicure’s pharmaceutical and pharmacy operations.
Medicure Inc. (TSXV:MPH)(OTC:MCUJF) has announced the signing of a definitive agreement to acquire Gateway Medical Pharmacy Inc. through its U.S. subsidiary, Medicure Pharma Inc. The agreement, signed on February 14, 2025, represents a strategic expansion of Medicure's direct-to-consumer pharmacy business.
Gateway generated unaudited revenue of approximately $3.1 million and net income of $271,000 for the 12-month period ended December 31, 2024. The acquisition aims to enhance Medicure's ZYPITAMAG® distribution, improve patient access, increase medication adherence, and reduce distribution costs.
The transaction requires no financing or debt acquisition by Medicure, and no finder fees will be paid. The closing is subject to various conditions, including the transfer of agreements and licenses to Medicure.
Medicure reported Q3 2024 financial results with total net revenue of $5.2 million, up from $5.0 million in Q3 2023. AGGRASTAT sales decreased to $1.9 million from $2.4 million, while Marley Drug business revenue increased to $2.7 million from $2.2 million. Net income rose to $680,000 ($0.07 per share) from $84,000 ($0.01 per share) year-over-year. However, adjusted EBITDA turned negative at -$467,000 compared to positive $429,000 in Q3 2023. Cash position decreased to $4.9 million from $6.4 million at year-end 2023.
Medicure (TSXV:MPH)(OTC PINK:MCUJF) has scheduled its Q3 2024 financial results presentation for November 26, 2024, at 8:30 AM ET. The Q3 financials will be filed after market close on November 25, 2024. The company also announced the resignation of Board member Kimberly Kramchynsky, effective November 18, 2024, citing personal reasons. The conference call will be accessible via toll-free and international numbers, with a webcast option available. A Q&A session will follow the presentation, and a recording will be available on the company's website afterward.
Medicure has announced a successful settlement of product development and supply contracts between its subsidiaries Medicure International Inc. & Medicure Pharma Inc. and an undisclosed third party. The company has received a €1.5 million settlement payment as part of the final agreement. The remaining terms of the settlement and the identity of the third party remain confidential.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) reported financial results for Q2 2024. Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023. AGGRASTAT sales declined to $1.8 million from $2.6 million. Marley Drug business revenue remained stable at $2.7 million. ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million. The company reported a net loss of $1.2 million ($0.12 per share) compared to a net income of $253,000 ($0.03 per share) in Q2 2023. Adjusted EBITDA was negative $514,000, down from $948,000. Cash and cash equivalents stood at $5.9 million as of June 30, 2024.
Medicure, a pharmaceutical company, announced an asset purchase agreement with CanAm Bioresearch to acquire patents and intellectual property related to new chemical entities for therapeutic use. Medicure will pay CanAm $100,000 upfront and up to $1.25 million in milestone payments, plus 10% of net proceeds from asset-related transactions, capped at $20 million. The deal includes the option for CanAm to repurchase the assets if Medicure fails to file an IND application within seven years. The agreement remains subject to regulatory approvals and customary closing conditions.
Medicure (TSXV:MPH) (OTC PINK:MCUJF) reported financial results for Q1 2024, ending March 31, 2024. The company recorded net revenue of $5.7 million, a slight increase from $5.6 million in Q1 2023. AGGRASTAT revenue fell to $2.3 million from $2.7 million, while Marley Drug revenue rose to $2.7 million from $2.3 million. Adjusted EBITDA decreased to $359,000 from $916,000, and net income dropped to $51,000 from $290,000. The decrease was attributed to higher expenses and lower AGGRASTAT sales. The company had $6.1 million in unrestricted cash as of March 31, 2024.
Additionally, all six nominees, including new director Kimberly Kramchynsky, were elected at the annual general meeting. The company will host a conference call on May 29, 2024, to discuss the results.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Medicure (MCUJF)?
What is the market cap of Medicure (MCUJF)?
